
Opinion|Videos|September 18, 2024
Evaluating Imaging Agents in Oligometastatic Prostate Cancer: A Comparative Analysis of Gallium-Based and Non-Gallium-Based Options
Author(s)Jaideep S. Sohi, MD, Jeremie Calais, MD
Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.
Advertisement
Video content above is prompted by the following:
- Can you discuss the advantages and limitations of different imaging agents commonly used in identifying oligometastatic disease in prostate cancer, such as gallium-based agents versus non-gallium-based agents?
- Are you aware of any differences in lesion detection rates or staging accuracy between gallium vs non- gallium-based PET imaging agents?
Advertisement
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
A Closer Look at the Evolution and Emerging Insights with Amyloid and Tau PET for Dementia and Alzheimer’s Disease
2
Study Suggests FDG-PET Better than CT for Assessing Treatment Response for Metastatic Breast Cancer
3
Rethinking Our Approach to Acquisitions of Coronary Computed Tomography Angiography (CCTA) Scans
4
Research Highlights from SCCT 2026
5










